Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, AVB-S6-500, combined with existing cancer treatment in patients with ovarian cancer that hasn't improved with other treatments. The goal is to see if this new combination works better than the existing treatments alone.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications, but you must wait at least 28 days after your last anti-cancer or hormonal therapy before starting the study drug.
Is the treatment generally safe for humans?
The treatment, which includes pegylated liposomal doxorubicin (PLD) and paclitaxel, has been studied in patients with breast cancer and is generally considered safe with manageable side effects. Common side effects include hand-foot syndrome (skin reaction on palms and soles), mouth sores, and low white blood cell counts, but no serious heart-related issues were observed.12345
What makes the drug AVB-S6-500 combined with Paclitaxel and Pegylated liposomal doxorubicin unique?
This drug combination is unique because it uses pegylated liposomal doxorubicin, which delivers the active ingredient directly to the tumor, reducing side effects compared to traditional doxorubicin. Additionally, the combination with paclitaxel has shown effectiveness in treating metastatic breast cancer with manageable side effects, especially in patients at high risk of heart-related issues.13678
What data supports the effectiveness of the drug AVB-S6-500, Paclitaxel, Taxol, Onxol, Abraxane, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Placebo, Control, Dummy Treatment?
Research shows that Abraxane, a form of paclitaxel, is effective in treating metastatic breast cancer with less toxicity compared to traditional paclitaxel. Additionally, combining pegylated liposomal doxorubicin (PLD) with paclitaxel has shown a high response rate and manageable side effects in patients with metastatic breast cancer.1891011
Who Is on the Research Team?
Amy Franke
Principal Investigator
Aravive, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1b Treatment
Open-label treatment with AVB-S6-500 in combination with PLD or Pac to evaluate safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AVB-S6-500
- Paclitaxel
- Pegylated liposomal doxorubicin (PLD)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aravive, Inc.
Lead Sponsor